Background: In the treatment of lung cancer, the effectiveness of chemotherapy is hampered by the development of therapy-resistance. Calcium is a universal second messenger involved in the regulation of virtually all cell function including apoptosis and cell death. Aim of this study was to investigate if the intracellular Ca2+-homeostasis of lung cancer cells may influence the development of therapy-resistance to cisplatin. Methods: ATP served as an agonist to stimulate squamous lung carcinoma cells (EPLC) and the increase in cytoplasmatic calcium ([Ca2+]c) was quantified using fluorescence microscopy. The Ca2+indicator rhod-2 was used to quantify the mitochondrial Ca2+-content. EPLC cells were exposed to 0.5, 1 and 2 µg/ml cisplatin for 3h simulating the in vivo pharmacokinetics. The Ca2+-chelator BAPTA was used to study the effects of a reduced [Ca2+]c on the effectiveness of cisplatin. Results: Using appropriate inhibitors, we could show that the ATPinduced Ca2+-increase was due to Ca2+-release from the sarcoplasmic reticulum involving IP3-and Ryanodine-receptors with Ca2+-influx from the extracellular space playing a minor role. Exposure to cisplatin led to a time dependent increase in the mitochondrial Ca2+-content. After 4 "cycles" of cisplatin the EPLC cells showed an increased survival compared to naïve EPLC cells. This therapy-resistance could be mimicked buffering [Ca2+]c with BAPTA. In the resistant clone, the ATP-induced Ca2+-increase was found to be significantly reduced compared to naïve cells. Conclusions: The intracellular Ca2+-homeostasis of lung carcinoma cells plays a significant role in the development of cisplatin-resistance and may therefore constitute a novel approach to overcome therapyresistance.
Purpose: Nodal status is an important prognostic factor and a major determinant for the staging and clinical management of NSCLC. The vascular endothelial growth factors (VEGFs) and the vascular endothelial growth factor receptors (VEGFRs) are important molecular markers in angiogenesis and lymphangiogenesis. In this study, we aimed to extensively investigate the correlations between lymph node metastasis and the VEGFs and VEGFRs in tumor cells as well as in the tumor stroma. Methods: Tumor tissue samples from 335 resected patients with stage I to IIIA were obtained and tissue microarrays were constructed from duplicate cores of tumor cells and surrounding stromal tissue from each resected specimen. Immunohistochemistry was used to evaluate the expression of VEGF-A, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2 and VEGFR-3. Results: There were 232 lymph node metastasis negative-and 103 lymph node metastasis positive patients (76 N1, 27 N2) . In univariate analyses (Chi-square test), high tumor cell expression of VEGF-A (P = .011) and VEGFR-3 (P < .001) correlated with lymph node metastasis. In tumor stroma, however, low expression of VEGF-A (P = .037) and VEGFR-3 (P = .033), correlated with lymph node metastasis. There were no significant correlations between tumor cell or stromal expression of VEGF-C, VEGF-D, VEGFR-1 or VEGFR-2 and lymph node metastasis. Though, high tumor cell expression of VEGFR-1 (P = .065) and low stromal expression of VEGFR-1 (P = .075) tended towards correlation with lymph node metastasis. In multivariate analyses (Binary logistic regression), including clinicopathogical variables and angiogenic markers, high tumor cell expression of VEGF-A (P = .032, HR 1.8, 95% CI 1.1-3.1), low stromal expression of VEGF-A (P = .025, HR 3.1, 95% CI 1.2 -8.3) and poor differentiation (P < .001, HR 3.4, 95% CI 2.0-5.9) correlated with lymph node positive patients. High tumor cell expression of VEGFR-3 (P < .001, HR 6.1, 95% CI 2.1-17.6) and vascular infiltration (P = .011, HR 3.9, 95% CI 1.4-11.2) correlated with N2 positivity. Conclusion: In tumor cells, there are strong correlations between high VEGFR-3 expression and N2-status and high VEGF-A expression and lymph node metastasis. While in stroma, low VEGF-A expression is associated with lymph node metastasis.
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Clinicopathologic Implications of minimal genomic alteration regions (MAR) identified in non-small cell lung cancer by using whole genome array-CGH were associated with poor survival. Multivariate analysis showed that alterations on 6p21, 7p, 9q, and 9p were remained as independent predictors for poor outcome. In addition, significant correlations were observed for 3 pairs of MARs (19q13 and 6p21, 19p13 and 19q13 , and 8p12 and 8q11), which indicated their possible collaborative roles. We examined the expression level of ECT2, one of the genes located in the most recurrently gained region on 3q26 by real-time qPCR. Expression of ECT2 was generally appeared to be up-regulated in NSCLCs.
Conclusion:
These results show that the novel genomic alterations identified in this study along with their clinicopathological implications would be useful to elucidate molecular mechanisms of lung cancer and to identify reliable biomarkers for clinical application. Although these subtypes can be distinguished readily at the histological level, knowledge of the genetic mechanisms underlying their differences will lead to the development of novel disease specific therapeutic strategies. Previous studies suggest that distinct patterns of genomic alteration exist for AC and SqCC. However, the specific genes responsible for the different tumor phenotypes remain largely unknown. Initial gene expression profiling studies have yielded some insight into the tumor subtypes and are able to segregate tumors into histologic groupings based on multi-gene models. Since not all gene expression changes are causal to disease development, it is challenging to distinguish critical events from reactive changes through global gene expression profiles alone. Thus, an integrative approach is necessary to fully understand the causal genetic events and downstream effects on disease phenotype. Objective: To comprehensively identify the underlying molecular differences between SqCC and AC using an integrative genome and transcriptome analysis. The discovery of genes differentially altered in each phenotype may clarify mechanisms of tumor differentiation and identify novel molecular targets for early diagnosis and therapy Methods: A whole genome tiling path CGH array was used to generate copy number profiles of 103 AC and 58 SqCC tumors. This array allows the detection of small segmental alterations such as micro-am-plifications and focal deletion which may have been undetected by conventional cytogenetic methods. Array data was visualized using SeeGH software and subjected to a smoothing computational algorithm to determine chromosomal areas of gain and loss. The resulting frequencies of alteration for each locus were compared between AC and SqCC using Fisher's Exact Test and regions with difference of p<0.001 were considered statistically significant. This genomic data was then integrated with genome wide expression data to identify genes deregulated as a result of copy number alterations specific to each NSCLC subtype. Results: Subtype specific copy number changes were identified. Regions of alteration disparity were mapped to chromosomes arms 2p, 3q, 4p, 4q, 8p, 12p, 19p, 19q, 20p and 22q . Analysis of expression data for the genes in these regions identified 183 unique genes differentially expressed between the subtypes as a result of copy number changes. Clustering and principle component analysis confirmed that these gene signatures were able to accurately delineate the disease subtypes. Grouping of these genes by biological function showed that many important pathways are differentially altered in AC and SqCC in disease specific ways. Conclusions: Whole genome array CGH comparison between AC and SqCC tumor genomes identified tumor subtype-specific genetic alterations. Integration of gene expression data delineated genes and pathways that could be important in phenotype differentiation. Characterization of these genes is now underway with the aim of defining new molecular targets for early diagnosis and treatment. Background: Prevention of primary tumour development remains to be the foundation for lung cancer control. Chemoprevention is defined as a pharmacologic intervention to suppress or reverse the carcinogenic process, and effective chemoprevention agents for lung cancer are needed. Due to effective public health campaigns for tobacco control, many lung cancers now arise in former smokers. We hypothesise that genomic changes common to current and former smokers represent authentic, permanent molecular changes altered by tobacco-smoke and may therefore represent crucial aberrations that lead to tobacco-smoke related lung carcinogenesis. Hence, the identification of these causal smoking-related lung cancer genes represent drug-able targets for the development of novel or natural chemoprevention agents for the prevention of lung cancer in former smokers. Methods: We analysed a total of 84 fresh tumour tissues from resected primary non-small cell lung carcinomas (NSCLCs): 46 current smokers (still smoking or quit less than one year prior to surgical resection), 26 former smokers (quit more than ten years prior to surgical resection), and 12 never smokers (smoked less than 100 cigarettes in lifetime). All smokers had at least 20 pack-years smoking history. Patients were matched on age (±10 years) and tobacco-smoke exposure (±10 pack-years). There was no significant difference in sex, histology, age or tobacco-smoke exposure between smoking groups. High molecular weight tumour DNA was digested, fluorescently labelled and
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